Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tafamidis

First Posted Date: 2017-08-30

Last Posted Date: 2018-05-14

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT03266705

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis
Healthy

Interventions: Drug: Crisaborole ointment 2%
Drug: Vehicle

First Posted Date: 2017-08-24

Last Posted Date: 2019-03-01

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT03260595

Locations: 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan

A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus (RSV) Infection

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Placebo
Drug: RV521

First Posted Date: 2017-08-23

Last Posted Date: 2025-02-05

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT03258502

Locations: 🇬🇧
hVIVO Services Ltd, London, United Kingdom

6-week Safety and PD Study in Adults With NAFLD

Phase 2

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: PF-06835919 High Dose
Drug: Placebo
Drug: PF-06835919 Low Dose

First Posted Date: 2017-08-22

Last Posted Date: 2019-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT03256526

Locations: 🇺🇸
WR-ClinSearch LLC, Chattanooga, Tennessee, United States
🇺🇸
Stand-Up MRI of Miami, Miami, Florida, United States
🇺🇸
Sterling Research Group, Ltd., Cincinnati, Ohio, United States

and more 5 locations

Absorption, Metabolism, Excretion and Absolute Bioavailability

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Absolute Bioavailability
Drug: PF-04965842

First Posted Date: 2017-08-15

Last Posted Date: 2017-12-21

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT03250039

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Phase 2

Completed

Conditions: Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: PF-05221304

First Posted Date: 2017-08-14

Last Posted Date: 2020-12-09

Lead Sponsor: Pfizer

Target Recruit Count: 305

Registration Number: NCT03248882

Locations: 🇨🇦
Discovery Clinical Services Ltd., Victoria, British Columbia, Canada
🇺🇸
South Denver Gastroenterology, P.C., Englewood, Colorado, United States
🇺🇸
ClinSearch, Chattanooga, Tennessee, United States

and more 134 locations

Understanding Hemophilia A and B Drug Dosage Administration Patterns

Terminated

Conditions: Hemophilia A
Hemophilia B

Interventions: Drug: Hemophilia B standard half-life
Drug: Hemophilia A standard half-life
Drug: Hemophilia B extended half-life
Drug: Hemophilia A extended half-life

First Posted Date: 2017-08-14

Last Posted Date: 2019-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 11

Registration Number: NCT03248141

Locations: 🇺🇸
University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸
Alliance for Childhood Diseases, dba Hemophilia Treatment Center of Nevada, Las Vegas, Nevada, United States
🇺🇸
Cook Children's Medical Center, Fort Worth, Texas, United States

Safety and Efficacy in Adult Subjects With Acute Migraines

Phase 3

Completed

Conditions: Migraine, With or Without Aura

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2017-08-03

Last Posted Date: 2023-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 1499

Registration Number: NCT03237845

Locations: 🇺🇸
Radiant Research, Inc., Anderson, South Carolina, United States
🇺🇸
Summit Research Network (Oregon), Inc., Portland, Oregon, United States
🇺🇸
Coastal Clinical Research, Mobile, Alabama, United States

and more 38 locations

Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-06700841

First Posted Date: 2017-08-02

Last Posted Date: 2017-10-25

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT03236493

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Safety and Efficacy Study in Adult Subjects With Acute Migraines

Phase 3

Completed

Conditions: Migraine, With or Without Aura

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2017-08-01

Last Posted Date: 2023-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 1485

Registration Number: NCT03235479

Locations: 🇺🇸
Neurological Physicians of Arizona/Radiant Research Inc, Gilbert, Arizona, United States
🇺🇸
Clinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States
🇺🇸
Clinical Research Institute, Minneapolis, Minnesota, United States

and more 44 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy